Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. / Ellrichmann, Mark; Kapelle, Mario; Ritter, Peter R; Holst, Jens Juul; Herzig, Karl-Heinz; Schmidt, Wolfgang E; Schmitz, Frank; Meier, Juris J.

In: The Journal of clinical endocrinology and metabolism, Vol. 93, No. 10, 10.2008, p. 3995-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ellrichmann, M, Kapelle, M, Ritter, PR, Holst, JJ, Herzig, K-H, Schmidt, WE, Schmitz, F & Meier, JJ 2008, 'Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations', The Journal of clinical endocrinology and metabolism, vol. 93, no. 10, pp. 3995-8. https://doi.org/10.1210/jc.2008-0924

APA

Ellrichmann, M., Kapelle, M., Ritter, P. R., Holst, J. J., Herzig, K-H., Schmidt, W. E., Schmitz, F., & Meier, J. J. (2008). Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. The Journal of clinical endocrinology and metabolism, 93(10), 3995-8. https://doi.org/10.1210/jc.2008-0924

Vancouver

Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig K-H, Schmidt WE et al. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. The Journal of clinical endocrinology and metabolism. 2008 Oct;93(10):3995-8. https://doi.org/10.1210/jc.2008-0924

Author

Ellrichmann, Mark ; Kapelle, Mario ; Ritter, Peter R ; Holst, Jens Juul ; Herzig, Karl-Heinz ; Schmidt, Wolfgang E ; Schmitz, Frank ; Meier, Juris J. / Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. In: The Journal of clinical endocrinology and metabolism. 2008 ; Vol. 93, No. 10. pp. 3995-8.

Bibtex

@article{50e74d10c9224a1996c0036431c529e2,
title = "Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations",
abstract = "INTRODUCTION: Intestinal lipase inhibition using tetrahydrolipstatin (Orlistat) has been widely used in the pharmacotherapy of morbid obesity. However, the effects of Orlistat on the secretion of appetite regulating gastrointestinal hormones and appetite sensations are still debated. We addressed whether Orlistat alters the secretion of glucagon-like peptide-1-(7-36)-amide (GLP-1), cholecystokinin (CCK), peptide YY (PYY), and ghrelin as well as postprandial appetite sensations.METHODS: Twenty-five healthy human volunteers were examined with a solid-liquid test meal after the oral administration of Orlistat or placebo. Gastric emptying, gallbladder volume and the plasma levels of CCK, PYY, GLP-1, and ghrelin were determined and appetite sensations were measured using visual analogue scales.RESULTS: Gastric emptying was accelerated by Orlistat administration (P < 0.0001), whereas gallbladder emptying was inhibited (P < 0.0001). Plasma levels of CCK (by approximately 53%), PYY (by approximately 40%), and GLP-1 (by approximately 20%) were significantly lowered by Orlistat (P < 0.001), whereas ghrelin levels were unaffected by Orlistat treatment (P = 0.18). Satiety and fullness were lowered by Orlistat (P < 0.0001), whereas appetite and prospective food consumption increased (P < 0.0001). The changes in CCK and PYY levels and the mean hunger ratings after Orlistat treatment were closely related to the inhibition of gallbladder motility.CONCLUSIONS: Orlistat alters gastric and gallbladder emptying and reduces the postprandial secretion of GLP-1, PYY and CCK. These changes in gastrointestinal hormone concentrations may raise appetite sensations and increase food consumption and should therefore be considered as potential side effects when applying lipase inhibitors for the treatment of morbid obesity.",
keywords = "Administration, Oral, Adult, Animals, Appetite, Cholecystokinin, Enzyme Inhibitors, Gastric Emptying, Glucagon-Like Peptide 1, Humans, Intestines, Lactones, Lipase, Peptide Fragments, Peptide YY, Placebos, Postprandial Period, Rats, Satiety Response, Time Factors",
author = "Mark Ellrichmann and Mario Kapelle and Ritter, {Peter R} and Holst, {Jens Juul} and Karl-Heinz Herzig and Schmidt, {Wolfgang E} and Frank Schmitz and Meier, {Juris J}",
year = "2008",
month = oct,
doi = "10.1210/jc.2008-0924",
language = "English",
volume = "93",
pages = "3995--8",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "10",

}

RIS

TY - JOUR

T1 - Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations

AU - Ellrichmann, Mark

AU - Kapelle, Mario

AU - Ritter, Peter R

AU - Holst, Jens Juul

AU - Herzig, Karl-Heinz

AU - Schmidt, Wolfgang E

AU - Schmitz, Frank

AU - Meier, Juris J

PY - 2008/10

Y1 - 2008/10

N2 - INTRODUCTION: Intestinal lipase inhibition using tetrahydrolipstatin (Orlistat) has been widely used in the pharmacotherapy of morbid obesity. However, the effects of Orlistat on the secretion of appetite regulating gastrointestinal hormones and appetite sensations are still debated. We addressed whether Orlistat alters the secretion of glucagon-like peptide-1-(7-36)-amide (GLP-1), cholecystokinin (CCK), peptide YY (PYY), and ghrelin as well as postprandial appetite sensations.METHODS: Twenty-five healthy human volunteers were examined with a solid-liquid test meal after the oral administration of Orlistat or placebo. Gastric emptying, gallbladder volume and the plasma levels of CCK, PYY, GLP-1, and ghrelin were determined and appetite sensations were measured using visual analogue scales.RESULTS: Gastric emptying was accelerated by Orlistat administration (P < 0.0001), whereas gallbladder emptying was inhibited (P < 0.0001). Plasma levels of CCK (by approximately 53%), PYY (by approximately 40%), and GLP-1 (by approximately 20%) were significantly lowered by Orlistat (P < 0.001), whereas ghrelin levels were unaffected by Orlistat treatment (P = 0.18). Satiety and fullness were lowered by Orlistat (P < 0.0001), whereas appetite and prospective food consumption increased (P < 0.0001). The changes in CCK and PYY levels and the mean hunger ratings after Orlistat treatment were closely related to the inhibition of gallbladder motility.CONCLUSIONS: Orlistat alters gastric and gallbladder emptying and reduces the postprandial secretion of GLP-1, PYY and CCK. These changes in gastrointestinal hormone concentrations may raise appetite sensations and increase food consumption and should therefore be considered as potential side effects when applying lipase inhibitors for the treatment of morbid obesity.

AB - INTRODUCTION: Intestinal lipase inhibition using tetrahydrolipstatin (Orlistat) has been widely used in the pharmacotherapy of morbid obesity. However, the effects of Orlistat on the secretion of appetite regulating gastrointestinal hormones and appetite sensations are still debated. We addressed whether Orlistat alters the secretion of glucagon-like peptide-1-(7-36)-amide (GLP-1), cholecystokinin (CCK), peptide YY (PYY), and ghrelin as well as postprandial appetite sensations.METHODS: Twenty-five healthy human volunteers were examined with a solid-liquid test meal after the oral administration of Orlistat or placebo. Gastric emptying, gallbladder volume and the plasma levels of CCK, PYY, GLP-1, and ghrelin were determined and appetite sensations were measured using visual analogue scales.RESULTS: Gastric emptying was accelerated by Orlistat administration (P < 0.0001), whereas gallbladder emptying was inhibited (P < 0.0001). Plasma levels of CCK (by approximately 53%), PYY (by approximately 40%), and GLP-1 (by approximately 20%) were significantly lowered by Orlistat (P < 0.001), whereas ghrelin levels were unaffected by Orlistat treatment (P = 0.18). Satiety and fullness were lowered by Orlistat (P < 0.0001), whereas appetite and prospective food consumption increased (P < 0.0001). The changes in CCK and PYY levels and the mean hunger ratings after Orlistat treatment were closely related to the inhibition of gallbladder motility.CONCLUSIONS: Orlistat alters gastric and gallbladder emptying and reduces the postprandial secretion of GLP-1, PYY and CCK. These changes in gastrointestinal hormone concentrations may raise appetite sensations and increase food consumption and should therefore be considered as potential side effects when applying lipase inhibitors for the treatment of morbid obesity.

KW - Administration, Oral

KW - Adult

KW - Animals

KW - Appetite

KW - Cholecystokinin

KW - Enzyme Inhibitors

KW - Gastric Emptying

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Intestines

KW - Lactones

KW - Lipase

KW - Peptide Fragments

KW - Peptide YY

KW - Placebos

KW - Postprandial Period

KW - Rats

KW - Satiety Response

KW - Time Factors

U2 - 10.1210/jc.2008-0924

DO - 10.1210/jc.2008-0924

M3 - Journal article

C2 - 18647814

VL - 93

SP - 3995

EP - 3998

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -

ID: 132048491